MCID: GLL022
MIFTS: 52

Guillain-Barre Syndrome malady

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Guillain-Barre Syndrome

About this section

Aliases & Descriptions for Guillain-Barre Syndrome:

Name: Guillain-Barre Syndrome 10 45 23 47 12 36 35 65
Acute Inflammatory Polyneuropathy 45 23 51
Guillain-Barré Syndrome 45 23 46
Gbs 45 23 2
Acute Inflammatory Demyelinating Polyradiculoneuropathy 45 51
Acute Inflammatory Demyelinating Polyneuropathy 45 65
Fisher Syndrome 23 46
Guillain-Barré Syndrome, Acute Inflammatory Demyelinating Polyradiculoneuropathic Form 51
Gbs, Acute Inflammatory Demyelinating Polyradiculoneuropathic Form 51
Acute Idiopathic Demyelinating Polyneuropathy 51
Acute Autoimmune Peripheral Neuropathy 45
Landry-Guillain-Barre-Strohl Syndrome 45
Acute Immune-Mediated Polyneuropathy 45
Acute Postinfectious Polyneuropathy 10
Acute Infective Polyneuritis Nos 10
 
Guillain-Barré-Strohl Syndrome 45
Group B Streptococcal Infection 65
Landry-Guillain-Barre Syndrome 23
Acute Inflammatory Neuropathy 45
Acute Infectious Polyneuritis 23
Landry's Ascending Paralysis 45
Acute Infective Polyneuritis 10
Post-Infectious Polyneuritis 10
Acute Autoimmune Neuropathy 65
Post-Infective Polyneuritis 45
Postinfectious Polyneuritis 10
Acute Inf. Polyneuritis 10
Miller Fisher Syndrome 65
Infectious Neuronitis 10
Aidp 51

Characteristics:

Orphanet epidemiological data:

51
acute inflammatory polyneuropathy:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age

Classifications:



External Ids:

Disease Ontology10 DOID:12842
ICD1027 G61.0
ICD9CM29 357.0
MeSH36 D020275
NCIt42 C26790
Orphanet51 98916
ICD10 via Orphanet28 G61.0
UMLS65 C0018378, C1963929, C3542501 C2020625, more

Summaries for Guillain-Barre Syndrome

About this section
NIH Rare Diseases:45 Guillain-barré syndrome is a rare disorder in which the body's immune system attacks part of the peripheral nervous system. symptoms include muscle weakness, numbness, and tingling sensations, which can increase in intensity until the muscles cannot be used at all. usually guillain-barré syndrome occurs a few days or weeks after symptoms of a viral infection. occasionally, surgery or vaccinations will trigger the syndrome. it remains unclear why only some people develop guillain-barré syndrome but there may be a genetic predisposition in some cases. diagnosed patients should be admitted to a hospital for early treatment. there is no cure for guillain-barré syndrome, but treatments such as plasma exchange (plasmapheresis) and high dose immunoglobulins may reduce the severity and duration of symptoms. recovery can take as little as a few days to as long as a few years. about 30% of those with guillain-barré syndrome have residual weakness. a small number may suffer a relapse many years after the initial attack. last updated: 1/16/2016

MalaCards based summary: Guillain-Barre Syndrome, also known as acute inflammatory polyneuropathy, is related to neuropathy, inflammatory demyelinating and psoriasis. An important gene associated with Guillain-Barre Syndrome is PMP22 (Peripheral Myelin Protein 22), and among its related pathways are Canonical NF-kappaB pathway and Neural Crest Differentiation. The drug immunoglobulins, intravenous has been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related mouse phenotypes are reproductive system and muscle.

Disease Ontology:10 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system.

MedlinePlus:35 Guillain-barre syndrome is a rare disorder that causes your immune system to attack your peripheral nervous system (pns). the pns nerves connect your brain and spinal cord with the rest of your body. damage to these nerves makes it hard for them to transmit signals. as a result, your muscles have trouble responding to your brain. no one knows what causes the syndrome. sometimes it is triggered by an infection, surgery, or a vaccination. the first symptom is usually weakness or a tingling feeling in your legs. the feeling can spread to your upper body. in severe cases, you become almost paralyzed. this is life-threatening. you might need a respirator to breathe. symptoms usually worsen over a period of weeks and then stabilize. guillain-barre can be hard to diagnose. possible tests include nerve tests and a spinal tap. most people recover. recovery can take a few weeks to a few years. treatment can help symptoms, and may include medicines or a procedure called plasma exchange. nih: national institute of neurological disorders and stroke

CDC:2 Group B Streptococcus (group B strep) is a type of bacteria that causes illness in people of all ages. Also known as GBS, group B strep disease is the most common cause of severe infections in newborns that can be deadly, but it can be prevented.

NINDS:46 Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barr

Genetics Home Reference:23 Guillain-Barré syndrome is an autoimmune disorder that affects the nerves. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In Guillain-Barré syndrome, the immune response damages peripheral nerves, which are the nerves that connect the central nervous system (the brain and spinal cord) to the limbs and organs. Specifically, the immune response affects a particular part of peripheral nerves called axons, which are the extensions of nerve cells (neurons) that transmit nerve impulses. Guillain-Barré syndrome can affect the neurons that control muscle movement (motor neurons); the neurons that transmit sensory signals such as pain, temperature, and touch (sensory neurons); or both. As a result, affected individuals can experience muscle weakness or lose the ability to feel certain sensations.

Wikipedia:68 Guillain–Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging... more...

Related Diseases for Guillain-Barre Syndrome

About this section

Diseases related to Guillain-Barre Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 280)
idRelated DiseaseScoreTop Affiliating Genes
1neuropathy, inflammatory demyelinating33.6MPZ, PMP22
2psoriasis30.6HLA-DQB1, HLA-DRB1
3fatty liver disease30.3CD40LG, HLA-DQB1, TNF
4systemic lupus erythematosus29.5CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1B
5pharyngeal-cervical-brachial variant of guillain-barré syndrome12.8
6paraparetic variant of guillain-barré syndrome12.7
7miller fisher syndrome12.0
8dysautonomia, familial10.8
9chronic inflammatory demyelinating polyneuropathy10.8
10zika virus infection10.6
11autonomic dysfunction10.6
12dysautonomia10.6
13congenital symblepharon10.5MPZ, PMP22
14prolymphocytic leukemia10.5MPZ, PMP22
15charcot-marie-tooth neuropathy type 2a10.5MPZ, PMP22
16pustulosis of palm and sole10.5TNF, TNFRSF1B
17cerebral sarcoidosis10.5TNF, TNFRSF1B
18acneiform dermatitis10.5TNF, TNFRSF1B
19gonococcal bursitis10.5TNF, TNFRSF1B
20multiple sclerosis 510.5TNF, TNFRSF1A
21anal colloid adenocarcinoma10.5MPZ, PMP22
22endotheliitis10.4
23neuropathy, recurrent, with pressure palsies10.4MPZ, PMP22
24central nervous system origin vertigo10.4MPZ, PMP22
25congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome10.4HLA-DRB1, TNF
26brain stem glioma10.4PMP22, TNF, TNFRSF1B
27microsomia hemifacial radial defects10.4HLA-DRB1, TNF
28hepatitis10.4
29retinitis10.4
30androgen insensitivity syndrome, mild10.4HLA-DRB1, TNF
31lujo hemorrhagic fever10.4HLA-DRB1, TNF
32autonomic peripheral neuropathy10.4MPZ, PMP22, TNF
33burns10.3
34allergic cutaneous vasculitis10.3PMP22, TNFRSF1A, TNFRSF1B
35telangiectasis10.3TNF, TNFRSF1A, TNFRSF1B
36rhizomelic dysplasia patterson lowry type10.3HLA-DRB1, TNF
37precursor b lymphoblastic lymphoma/leukemia10.3TNF, TNFRSF1A, TNFRSF1B
38sheehan syndrome10.3PMP22, TNFRSF1A, TNFRSF1B
39tibial nerve palsy10.3PMP22, TNFRSF1A, TNFRSF1B
40pyosalpinx10.3TNF, TNFRSF1A, TNFRSF1B
41rhabdoid cancer10.3TNFRSF1A, TNFRSF1B
42lichen planus pemphigoides10.3HLA-DQB1, HLA-DRB1
43heavy chain deposition disease10.3HLA-DQB1, HLA-DRB1
44neuroblastoma10.3
45prostate cancer10.3
46breast cancer10.3
47keratitis10.3
48multiple myeloma10.3
49leukemia10.3
50myeloma10.3

Graphical network of the top 20 diseases related to Guillain-Barre Syndrome:



Diseases related to guillain-barre syndrome

Symptoms for Guillain-Barre Syndrome

About this section

Drugs & Therapeutics for Guillain-Barre Syndrome

About this section

Drugs for Guillain-Barre Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1VaccinesPhase 4, Phase 36085
2ImmunoglobulinsPhase 3, Phase 24477
3AntibodiesPhase 3, Phase 24477
4Immunologic FactorsPhase 318483
5
DalfampridineapprovedPhase 262504-24-51727
Synonyms:
.gamma.-Aminopyridine
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 AP
4 Aminopyridine
4 Aminopyridine Sustained Release
4-AP
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-Pyridinamine
4-Pyridylamine
4-aminopyridine
5-22-09-00106 (Beilstein Handbook Reference)
504-24-5
A 0152
A0414
A78403_ALDRICH
AB1004971
AC-907/25014071
AC1L1C3R
AC1Q52BM
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
BRN 0105782
BSPBio_001562
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
C13728
C5H6N2
CHEBI:34385
CHEMBL284348
CID1727
Caswell No. 038
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
FT-0083754
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine SR
Fampridine [USAN:INN]
Fampridine-PR
Fampridine-SR
Fampridinum
Fampyra
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
 
KBio1_000572
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
LS-130202
Lopac-A-0152
Lopac0_000032
MLS000069400
Mi-W-3
MolPort-000-146-022
N07XX07
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
NINDS_000572
NSC 15041
NSC15041
Neurelan
Neurelan (TN)
P-Aminopyridine
PYRIDINE,4-AMINO
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
SPECTRUM1501130
STK298717
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
Spectrum_000155
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 10-3
VMI 103
VMI-10-3
VMI-103
VMI103
WLN: T6NJ DZ
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
gamma-Aminopyridine
nchem.892-comp4
p-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
pyridin-4-amine
pyridin-4-ylamine
6Rho(D) Immune GlobulinPhase 2206
7Potassium Channel BlockersPhase 2151
8Immunoglobulins, IntravenousPhase 2211
9Pharmaceutical SolutionsPhase 27004
10Complement System ProteinsPhase 2190
11
Thiamineapproved, nutraceutical8859-43-81130
Synonyms:
100660-17-1
115461-66-0
1sbr
2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol
2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydrox yethyl)-4-methylthiazolium chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethylthiazolium chloride, monohydrochloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride monohydrochloride
3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM
3-(4-AMINO-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium
3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride hydrochloride
3[(4-Amino-2-methyl-5-pyrimidinyl)-methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride
55463-15-5
57777-32-9
59-43-8
67-03-8
AC-11683
AC1L1ASK
AC1L1LOC
AC1LAODT
AC1Q4V9Q
AI3-18993
AKOS000668650
AR-1L8201
Aneurin
Aneurine
Antiberiberi factor
Apatate drape
Apate drops
B-Amin
BAS 00266240
BPBio1_000686
BSPBio_000622
Beatine
Bedome
Begiolan
Beivon
Benerva
Bequin
Berin
Betabion
Betalin S
Betaxin
Bethiamin
Bethiazine
Beuion
Bevitex
Bevitine
Bewon
Biamine
Bithiamin
Biuno
Bivatin
Bivita
C00378
C12H17N4OS
CCRIS 1906
CCRIS 5823
CHEBI:18385
CHEBI:33283
CHEBI:49105
CHEMBL1547
CHEMBL1588
CID1130
CID517305
CID6042
Cernevit-12
Chloride-hydrochloride salt of thiamine
Clotiamina
D08580
DB00152
EINECS 200-425-3
EINECS 200-641-8
Eskapen
Eskaphen
FEMA No. 3322
HSDB 220
 
Hybee
I14-14339
LS-3226
LT00233141
Lixa-beta
MLS001304099
Metabolin
MolPort-000-722-048
MolPort-001-920-086
MolPort-002-052-059
NChemBio.2007.13-comp10
NSC 36226
NSC36226
Oryzanin
Oryzanine
Prestwick0_000631
Prestwick1_000631
Prestwick2_000631
Prestwick3_000631
SBB058094
SMP1_000084
SMR000718788
SPBio_002841
ST095175
Slowten
THD
THIAMIN, VITAMIN B1
Thiadoxine
Thiamin
Thiamin dichloride
Thiaminal
Thiamine
Thiamine (INN)
Thiamine HCL
Thiamine Hydrochloride
Thiamine [INN:BAN]
Thiamine chloride
Thiamine chloride hydrochloride
Thiamine dichloride
Thiamine hydrochloride [JAN]
Thiamine monochloride
Thiamine monohydrochloride
Thiamine, chloride
Thiamine, chloride, hydrochloride
Thiamine, monohydrochloride
Thiaminium
Thiaminium chloride hydrochloride
Thiaminum
Thiaminum [INN-Latin]
Thiamol
Thiavit
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethyl, chloride, monohydrochloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride (1:1)
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-, chloride, monohydrochloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-chloride
Tiamidon
Tiamina
Tiamina [INN-Spanish]
Tiaminal
TimTec1_000613
Trophite
UNII-X66NSO3N35
VIB
Vetalin S
Vinothiam
Vitamin B1
Vitamin B1 (TN)
Vitamin B1 hydrochloride (VAN)
Vitaneurin
Vitaneuron
ZINC00049153
[5-[[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]methyl]-2-methylpyrimidin-4-yl]azanium dichloride
bmse000274
nchembio.121-comp5
thiamin
thiamine
thiamine(1+)
thiamine(1+) ion
thiaminium
vitamin B1
vitamin b1(thiamine)
12Chelating Agents667
13Anticoagulants1760
14Calcium, Dietary4678
15Vitamins3857
16Vitamin B Complex2847
17Immunoglobulin G146
18Autoantibodies117
19
Citric Acidnutraceutical100177-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
20CitrateNutraceutical1001
21ThiaminNutraceutical88

Interventional clinical trials:

(show all 31)
idNameStatusNCT IDPhase
1Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of AgeCompletedNCT01985997Phase 4
2Efficacy and Safety Study of GB-0998 for Guillain-Barré SyndromeCompletedNCT02342184Phase 3
3Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801CompletedNCT01604746Phase 3
4Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré SyndromeRecruitingNCT02221271Phase 3
5Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary VaccinationActive, not recruitingNCT01777308Phase 3
6Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primaActive, not recruitingNCT01934140Phase 3
7Early Mechanical Ventilation for Guillain Barré SyndromeCompletedNCT00167622Phase 2
8Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridineCompletedNCT00056810Phase 2
9Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) PatientsRecruitingNCT02780570Phase 2
10Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome StudyRecruitingNCT02029378Phase 2
11JET-GBS - Japanese Eculizumab Trial for GBSActive, not recruitingNCT02493725Phase 2
12Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)CompletedNCT01306578
13Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome.CompletedNCT01024088
14Brain Computer Interface for Communication in ICU: a Feasibility StudyCompletedNCT01005524
15Regional Citrate Anticoagulation in Plasma Exchange TreatmentCompletedNCT01370200
16Cervarix Long-term Safety SurveillanceCompletedNCT01498627
17Surveillance for Adverse Events Following Pandemic H1N1 ImmunizationCompletedNCT01289418
18Surveillance for Adverse Events Following Influenza ImmunizationCompletedNCT01318876
19Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United KingdomCompletedNCT01953822
20International Guillain-Barré Syndrome Outcome StudyRecruitingNCT01582763
21sCD163 as a Potential Biomarker in Guillain- Barré SyndromeRecruitingNCT02582853
22The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin InnervationRecruitingNCT00173199
23Thiamin (Vitamin B1) Levels in Eating Disorder Adolescent PatientsRecruitingNCT02164487
24Safety Study of GBS Following Menactra Meningococcal VaccinationActive, not recruitingNCT00575653
25Change of Nerve Conduction Properties in IVIg Dependent NeuropathiesActive, not recruitingNCT01655394
26Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling by invitationNCT02422875
27Processing Integration in Neurological Patients Using fMRINot yet recruitingNCT02722070
28Perception and Multisensory Integration in Neurological Patients Using fMRINot yet recruitingNCT01469858
29Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions.Not yet recruitingNCT01516385
30Gastrointestinal Transit Time in Patients With Guillain-Barré SyndromeSuspendedNCT02459808
31Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre SyndromeTerminatedNCT00004833

Search NIH Clinical Center for Guillain-Barre Syndrome

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: guillain-barre syndrome

Genetic Tests for Guillain-Barre Syndrome

About this section

Anatomical Context for Guillain-Barre Syndrome

About this section

MalaCards organs/tissues related to Guillain-Barre Syndrome:

33
Brain, Spinal cord, Testes, Heart, T cells, Skin, Bone

Animal Models for Guillain-Barre Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Guillain-Barre Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053898.0CD40LG, HLA-DQB1, MBP, MPZ, PMP22, TNF
2MP:00053697.8HCRT, HLA-DQB1, PMP22, TNF, TNFRSF1A, TNFRSF1B
3MP:00053847.2CD40LG, HLA-DQB1, HP, MBP, MPZ, PMP22
4MP:00036317.1CD40LG, HCRT, HLA-DQB1, MBP, MPZ, PMP22
5MP:00053976.6CD40LG, HLA-DQA1, HLA-DQB1, HP, MBP, MPZ
6MP:00053876.3CD40LG, HLA-DQA1, HLA-DQB1, HP, MBP, MPZ

Publications for Guillain-Barre Syndrome

About this section

Articles related to Guillain-Barre Syndrome:

(show top 50)    (show all 154)
idTitleAuthorsYear
1
Effect of spinal stabilization exercise on dynamic postural control and visual dependency in subjects with chronic non-specific low back pain. (27210863)
2016
2
LTA + 252A > G polymorphism is associated with risk of nasal NK/T-cell lymphoma in a Chinese population: a case-control study. (26108796)
2015
3
Lipoid proteinosis in a Chinese patient. (24521736)
2014
4
miR-125b targets ARID3B in breast cancer cells. (22307404)
2012
5
Leukocyte mitochondrial DNA alteration in systemic lupus erythematosus and its relevance to the susceptibility to lupus nephritis. (22942739)
2012
6
Risk stratification for invasive aspergillosis in immunocompromised patients. (23231711)
2012
7
Diagnostic utility of C-reactive protein combined with brain natriuretic peptide in acute pulmonary edema: a cross sectional study. (21696613)
2011
8
Histidine-rich glycoprotein polymorphism and pregnancy outcome: a pilot study. (21665544)
2011
9
Age-associated cerebral atrophy in mouse lemur primates. (19564059)
2011
10
Bilateral Rasmussen encephalitis. (21216675)
2011
11
Participation of cysteine protease cathepsin L in the gel disintegration of red bulleye (Priacanthus macracanthus) surimi gel paste. (20355055)
2010
12
Predictors of atrial tachyarrhythmias in subjects with type 1 ECG pattern of Brugada syndrome. (19335860)
2009
13
Liposarcoma arising in the foot: a case report. (19902014)
2009
14
Signaling "cross-talk" is integrated by transcription factors in the development of the anterior segment in the eye. (19623614)
2009
15
A rare case of lumbar vertebral lymphangioma presenting as chylothorax. (19243995)
2009
16
Perspectives in treatment of AL amyloidosis. (18162121)
2008
17
Clinical speech impairment in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy. (18688134)
2008
18
Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. (18245533)
2008
19
Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. (18235249)
2008
20
The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe. (17556368)
2007
21
Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. (17475604)
2007
22
Pathogenesis of amniotic band syndrome. (17689662)
2007
23
Intermittent exotropia: comparative surgical results of lateral recti-recession and monocular recess-resect. (17768548)
2007
24
Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations. (17060935)
2006
25
Similar effects of general and spinal anaesthesia on perioperative stress response in patients undergoing haemorrhoidectomy. (16864910)
2006
26
Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. (16817839)
2006
27
A new synthesis of alpha-arbutin via Lewis acid catalyzed selective glycosylation of tetra-O-benzyl-alpha-D-glucopyranosyl trichloroacetimidate with hydroquinone. (16697994)
2006
28
Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. (16114026)
2005
29
Phosphoinositide recognition domains. (12694559)
2003
30
Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. (12495931)
2003
31
The diagnostic problem of endometrial stromal sarcoma: report on six cases. (12821339)
2003
32
Malonyl CoA decarboxylase deficiency: C to T transition in intron 2 of the MCD gene. (11550227)
2001
33
Plasminogen activator inhibitor-1 and haemostasis in obesity. (11681808)
2001
34
Radiological case of the month. Adrenal adenoma. (9549972)
1998
35
Enzyme-based assay for quantification of paraoxon in blood of parathion poisoned patients. (9988368)
1998
36
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. (9667969)
1998
37
5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. (8636334)
1996
38
Studies on the in vitro phosphorylation of HSSB-p34 and -p107 by cyclin-dependent kinases. Cyclin-substrate interactions dictate the efficiency of phosphorylation. (8798463)
1996
39
Resistant respiratory pathogens and extended-spectrum antibiotics. (7484684)
1995
40
Clinical evaluations of a new ovarian cancer marker, COX-1. (7589737)
1995
41
Duct-acinar-islet cell tumor of the pancreas. (8548040)
1995
42
Nuclear localization and cell cycle regulation of a murine protein tyrosine phosphatase. (8164659)
1994
43
Trimetrexate for Pneumocystis carinii pneumonia in patients with AIDS. (1532518)
1992
44
A method for production of antibodies to human T-cell receptor beta-chain variable regions. (1656442)
1991
45
Partial transposition of the penis and scrotum with anterior urethral diverticulum in a child born with the caudal regression syndrome. (2627212)
1989
46
Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. (6752799)
1982
47
Atypical angiomatosis retinae. Positive blanch test. (1200900)
1975
48
Summary of recent abstracts. IX. Helminthiasis. Trematode infections and cestode infections. (4944786)
1971
49
Atlanto-occipital fusion, basilar impression, and block vertebrae associated with intraspinal neurofibroma, meningocele, and von Recklinghausen's disease. (13846742)
1960
50
Gonorrhea complicating pregnancy and its relation to ophthalmia neonatorum. (18878572)
1948

Variations for Guillain-Barre Syndrome

About this section

Expression for genes affiliated with Guillain-Barre Syndrome

About this section
Search GEO for disease gene expression data for Guillain-Barre Syndrome.

Pathways for genes affiliated with Guillain-Barre Syndrome

About this section

Pathways related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 29)
idSuper pathwaysScoreTop Affiliating Genes
19.7TNF, TNFRSF1A
29.6MBP, MPZ, PMP22
39.4CD40LG, TNF, TNFRSF1A
49.4CD40LG, TNFRSF1A, TNFRSF1B
5
Show member pathways
9.4TNF, TNFRSF1A, TNFRSF1B
6
Show member pathways
9.4TNF, TNFRSF1A, TNFRSF1B
79.4TNF, TNFRSF1A, TNFRSF1B
89.4TNF, TNFRSF1A, TNFRSF1B
99.4TNF, TNFRSF1A, TNFRSF1B
10
Show member pathways
9.4TNF, TNFRSF1A, TNFRSF1B
11
Show member pathways
9.4TNF, TNFRSF1A, TNFRSF1B
129.4TNF, TNFRSF1A, TNFRSF1B
13
Show member pathways
9.1CD40LG, TNF, TNFRSF1A, TNFRSF1B
14
Show member pathways
9.1CD40LG, TNF, TNFRSF1A, TNFRSF1B
15
Show member pathways
9.1CD40LG, TNF, TNFRSF1A, TNFRSF1B
16
Show member pathways
9.1CD40LG, TNF, TNFRSF1A, TNFRSF1B
178.5HLA-DQA1, HLA-DQB1, HLA-DRB1
188.5HLA-DQA1, HLA-DQB1, HLA-DRB1
19
Show member pathways
8.5HLA-DQA1, HLA-DQB1, HLA-DRB1
208.5HLA-DQA1, HLA-DQB1, HLA-DRB1
21
Show member pathways
8.2CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1
228.2HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
238.0CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, MPZ
24
Show member pathways
7.8HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
257.8HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
267.8HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
27
Show member pathways
7.7HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
28
Show member pathways
7.5CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
29
Show member pathways
7.1CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A

GO Terms for genes affiliated with Guillain-Barre Syndrome

About this section

Cellular components related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class II protein complexGO:00426139.5HLA-DQA1, HLA-DQB1
2integral component of lumenal side of endoplasmic reticulum membraneGO:00715569.3HLA-DQA1, HLA-DQB1
3trans-Golgi network membraneGO:00325888.5HLA-DQA1, HLA-DQB1, HLA-DRB1
4ER to Golgi transport vesicle membraneGO:00125078.2HLA-DQA1, HLA-DQB1, HLA-DRB1

Biological processes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1regulation of immunoglobulin secretionGO:005102310.4CD40LG, TNF
2regulation of establishment of endothelial barrierGO:190314010.2TNF, TNFRSF1A
3death-inducing signaling complex assemblyGO:007155010.1TNF, TNFRSF1A
4positive regulation of ceramide biosynthetic processGO:200030410.0TNF, TNFRSF1A
5antigen processing and presentation of peptide or polysaccharide antigen via MHC class IIGO:00025049.9HLA-DQA1, HLA-DRB1
6immunoglobulin production involved in immunoglobulin mediated immune responseGO:00023819.7HLA-DQB1, HLA-DRB1
7establishment of protein localization to plasma membraneGO:00900029.6TNF, TNFRSF1A
8extrinsic apoptotic signaling pathway via death domain receptorsGO:00086259.4TNF, TNFRSF1A
9intrinsic apoptotic signaling pathway in response to DNA damageGO:00086309.4TNF, TNFRSF1A, TNFRSF1B
10regulation of cell proliferationGO:00421279.4TNF, TNFRSF1A, TNFRSF1B
11antigen processing and presentationGO:00198828.8HLA-DQA1, HLA-DQB1, HLA-DRB1

Sources for Guillain-Barre Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet